Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.

This study has been completed.
Information provided by (Responsible Party):
GTx Identifier:
First received: April 30, 2007
Last updated: June 26, 2014
Last verified: June 2014
The purpose of this study is to assess if Gtx-024 is effective in increasing lean body mass in subjects with muscle wasting related to cancer.

Condition Intervention Phase
Drug: GTx-024
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: Double-Blind, Placebo-Controlled, Dose-Finding Study of the Effect of GTx-024 on Muscle Wasting (Cachexia) in Patients With Cancer

Resource links provided by NLM:

Further study details as provided by GTx:

Primary Outcome Measures:
  • The Efficacy of GTx-024 on Total Body Lean Mass. [ Time Frame: Baseline to Four Months ]
    Change in total body lean mass as measured by dual energy x-ray absorptiometry (DEXA)from baseline to 4 months.

Secondary Outcome Measures:
  • To Assess the Efficacy of GTx-024 on Muscle Function (Performance) as Measured by Stair Climb. [ Time Frame: Four Months ]
    Change in stair climb power from baseline to 4 months. Stair climb power is defined power (watts)=[9.8 m/sec**2]*[weight (kg)]*[height of 12 steps(meters)]/ [time (seconds) up the 12 steps].

Enrollment: 159
Study Start Date: May 2007
Study Completion Date: September 2008
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
1 mg GTx-024
Drug: GTx-024
1 mg GTx 024
Experimental: 2
3 mg GTx-024
Drug: GTx-024
3 mg GTx-024
Placebo Comparator: 3
Drug: Placebo
Matching Placebo

Detailed Description:

Cancer cachexia is characterized by a hypermetabolic state that leads to catabolism that is responsible for reductions in lean mass.These catabolic changes are accompanied by an increase in total energy expenditure, but a decrease in voluntary energy expenditure that ultimately results clinically in cachexia and its symptoms of lethargy, fatigue, weakness and general malaise (Kotler DP. Cachexia. Ann Intern Med. 2000; 133:622-634).

The prevalence of cachexia increases from 50 percent at presentation to more than 80 percent before death from malignancy. In over 20 percent of cancer patients, cachexia is the cause of death (Bruera E. Anorexia, cachexia and nutrition. Br Med J 1997;315:1219-1222). Cancer cachexia leads to shorter survival, decreased response rates and increased toxicity to chemotherapy, weakness, and an overall decreased quality of life (DeWys et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980 Oct;69(4):491-7). The purpose of this study is to assess the efficacy of GTx-024 on total body lean mass. Secondary endpoints include but are not limited to assessment of GTx-024 on muscle function, total body weight and total body fat mass.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

To be eligible for participation in this study, subjects must meet all of the following criteria:

  • have been diagnosed with Stage 2, 3 or 4 non-small cell lung cancer or Stage 2, 3 or 4 colorectal cancer or non-hodgkin's lymphoma or chronic lymphocytic leukemia or Stage 3 or 4 breast cancer.
  • be prior to initiation of or between cycles of chemotherapy.
  • have experienced greater than or equal to 2% weight loss from the highest patient reported weight in the 6 months prior to screening for Protocol G200502 (Wt = body weight)

    % weight loss = (Wt at screening - highest Wt in last 6 months) / highest Wt in last 6 months x 100%

  • If surgery is part of the cancer treatment, screening for this study should be conducted at least 2 weeks (14 days) after surgery.
  • have a life expectancy of >6 months
  • FEMALES - be clinically confirmed as postmenopausal
  • MALES - over 45 years of age
  • ECOG score ≤1

Exclusion Criteria:

Subjects with any of the following will NOT be eligible for enrollment in this study:

  • history of active/uncontrolled congestive heart failure, chronic hepatitis, hepatic cirrhosis, or HIV infection
  • Cardiovascular: No uncontrolled hypertension
  • Positive screen for Hepatitis B consisting of HBsAg (Hepatitis B Surface Antigen), anti-HCV (Hepatitis C Antibody), hepatitis A antibody IgM, or HIV
  • Currently taking testosterone, OXANDRIN® (oxandrolone), testosterone-like agents (such as DHEA, androstenedione, and other androgenic compounds, including herbals), or antiandrogens (Please note that previous therapy with testosterone and testosterone-like agents is acceptable with a 30 day wash-out. However, if the previous testosterone therapy was a long-term depot, within the past 6 months, the site should call the medical monitor for this study to determine appropriate washout period.)
  • Currently taking megestrol acetate (MEGACE®), dronabinol (MARINOL®), or any prescription medication intended to increase appetite or treat unintentional weight loss
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00467844

  Hide Study Locations
United States, Alaska
Alaska Cancer Research and Education Center
Anchorage, Alaska, United States, 99508
United States, Arkansas
Highlands Oncology Group
Fayetteville, Arkansas, United States, 72703
United States, California
Compassionate Cancer Care
Corona, California, United States, 92882
Compassionate Cancer Care Medical Group
Fountain Valley, California, United States, 92708
Pacific Coast Hematology/Oncology Medical Group, Inc.
Fountain Valley, California, United States, 92708
Desert Hematology Oncology Medical Group
Rancho Mirage, California, United States, 92270
Compassionate Cancer Care
Riverside, California, United States, 92501
United States, Colorado
Penrose Cancer Center
Colorado Springs, Colorado, United States, 80907
Dorcy Cancer Center
Pueblo, Colorado, United States, 81004
United States, Connecticut
Hartford Hospital Cancer Clinical Research Office
Hartford, Connecticut, United States, 06102
Medical Oncology & Hematology, PC
Waterbury, Connecticut, United States, 06708
United States, Florida
Gainesville Hematology Oncology Associates
Gainesville, Florida, United States, 32605
Horizon Institute for Clinical Research
Hollywood, Florida, United States, 33021
Hematology Oncology Associates
Lake Worth, Florida, United States, 33461
The Radiation Oncology Group
Lake Worth, Florida, United States, 33461
Watson Clinic LLP, Center for Cancer Care & Research
Lakeland, Florida, United States, 33805
Osler Medical
Melbourne, Florida, United States, 32901
Innovative Medical Research of South Florida, Inc.
Miami, Florida, United States, 33179
Florida Medical Clinic, PA
Zephyrhills, Florida, United States, 33542
United States, Georgia
Augusta Oncology Associates
Augusta, Georgia, United States, 30901
Dublin Hematology and Oncology
Dublin, Georgia, United States, 31021
United States, Kansas
Cancer Center of Kansas
Wichita, Kansas, United States, 67214
United States, Kentucky
Kentuckiana Cancer Institute
Louisville, Kentucky, United States, 40202
United States, Maryland
Johns Hopkins University Clinical Trial Unit
Baltimore, Maryland, United States, 21287
Center for Cancer & Blood Disorders
Bethesda, Maryland, United States, 20817
The Center for Clinical Research WA County Hospital
Hagerstown, Maryland, United States, 21740
United States, Michigan
Newland Medical Center
Southfield, Michigan, United States, 48075
United States, Mississippi
The West Clinic
Corinth, Mississippi, United States, 38834
West Clinic
Corinth, Mississippi, United States, 38834
The West Clinic
Southaven, Mississippi, United States, 38671
West Clinic
Southaven, Mississippi, United States, 38671
Hematology & Oncology Associates at Bridgeport
Tupelo, Mississippi, United States, 38801
United States, Missouri
Heartland Hematology-Oncology Associates
Kansas City, Missouri, United States, 64118
United States, Montana
Donald H. Berdeaux, MD, FACP, PC
Great Falls, Montana, United States, 59405
Great Falls Clinic, LLP - Clinic Cancer Care
Great Falls, Montana, United States, 59405
United States, Nebraska
Creighton University Hematology/Oncology Clinic
Omaha, Nebraska, United States, 68131
United States, North Carolina
Cancer Care of Western North Carolina
Ashville, North Carolina, United States, 28801
Four Seasons Hospice & Palliative Care
Flat Rock, North Carolina, United States, 28731
Hanover Medical Specialists
Wilmington, North Carolina, United States, 28401
United States, Ohio
Gabrail Cancer Center
Canton, Ohio, United States, 44718
Signal Point Clinical Research Center, LLC
Middletown, Ohio, United States, 45042
Hematology Oncology Consultants
Worthington, Ohio, United States, 43235
United States, Pennsylvania
Consultants in Medical Oncology and Hematology
Drexel Hill, Pennsylvania, United States, 19026
Urological Associates of Lancaster
Lancaster, Pennsylvania, United States, 17604
Berks Hematology-Oncology Associates
West Reading, Pennsylvania, United States, 19611
United States, South Carolina
Charleston Hematology Oncology Associates
Charleston, South Carolina, United States, 29403
United States, Tennessee
West Clinic
Memphis, Tennessee, United States, 38104
West Clinic
Memphis, Tennessee, United States, 38120
United States, Texas
Dallas Oncology Consultants
Dallas, Texas, United States, 75237
United States, Washington
Providence Everett Medical Center, Cancer Research Department
Everett, Washington, United States, 98201
Canada, Alberta
University of Alberta Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Canada, Ontario
Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9
Sponsors and Collaborators
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: GTx Identifier: NCT00467844     History of Changes
Obsolete Identifiers: NCT00832104
Other Study ID Numbers: G200502
Study First Received: April 30, 2007
Results First Received: January 18, 2013
Last Updated: June 26, 2014

Keywords provided by GTx:
Muscle Wasting
Non-Small Cell Lung Cancer
Colorectal Cancer
Non-Hodgkin's Lymphoma
Stage 3 or 4 Breast Cancer
Chronis Lymphocytic Leukemia

Additional relevant MeSH terms:
Muscular Atrophy
Weight Loss
Body Weight Changes
Body Weight
Signs and Symptoms
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Pathological Conditions, Anatomical processed this record on April 24, 2017